A phase 1a trial reported one-year lipid reductions after CTX310
In a phase 1a trial, a one-time CRISPR-Cas9 treatment with CTX310 was associated with sustained reductions in ANGPTL3 and atherogenic lipids at one year. The report found no treatment-related dose-limiting toxic effects, but this was an early-phase study and does not establish long-term safety or clinical benefit.
The record ends here. Everything below this line is invented.
What if a permanent edit could replace one daily pill but not erase a family’s fear?
Part one
The Cut Sequence
At 06:00, Ana set her pill organizer beside the clinic's consent screen. Her doctor was offering a one-time edit of ANGPTL3 in adult liver cells, an approach intended to lower blood lipids. A small phase 1a study had shown sustained lipid reductions after a single CRISPR treatment, but it had not established long-term safety or clinical benefit.
By 2048, years of follow-up had brought the intervention into a carefully limited adult program. Ana had managed her numbers with daily medicine for decades; her daughter had inherited the family's caution, not the edit. The treatment would not change her daughter's DNA, but it could change what Ana believed she owed her.
The clinician turned the screen toward her: sign today, or keep taking the tablets while longer results accumulated. Ana's daughter had packed the old pill case for a school trip, as if the family would always need it. Ana clicked the consent box. The screen asked who should receive the ten-year update; she typed her daughter's name, then stopped before pressing send.
What’s real
- CTX310 targets ANGPTL3 with CRISPR-Cas9 editing.
- The phase 1a report described one-year lipid reductions.
- The study does not establish long-term safety or benefit.
What’s invented
- Ana, her daughter, and the adult program are fictional.
- The future treatment availability and family update are invented.
- The reported edit did not alter a patient’s inherited DNA.
Part two: The Ten-Year Update
Part two isn’t on sale yet. Check back soon.
Filed under medicine, gene editing, cardiology.